TY -的A2吴Guangzhen AU - Fu Shengqiang盟——刘,逸夫盟——张,志诚盟——美,明非盟-陈,羌族非盟-王,本盟,杨Xiaorong盟——太阳,Ting AU - Ma,明非盟-谢,蕴结PY - 2022 DA - 2022/12/26 TI -识别小说Myc-Regulated肾肾透明细胞癌患者的基因签名SP - 3487859六世- 2022 AB -鉴于myc已知致癌基因在几个癌症包括肾肾透明细胞癌(KIRC)。我们旨在构建myc-regulated基因(著)的预后签名。我们获得了mRNA表达和临床数据的KIRC癌症基因组图谱(TCGA)从分子签名数据库数据库和著(MSigDB)。然后,预后签名组成的8著(IRF9、UBE2C YBX3, CDKN2B, CKAP2L, CYFIP2, FBLN5,和PDLIM7)是由微分表达式分析,cox回归分析,至少绝对收缩和选择算子(套索)分析。KIRC患者分为高和低风险组基于风险得分MRGs-based签名。患者的高危人群亚临床特点和生存。此外,KIRC风险评分是一个独立的预后因素,和基于风险评分=列线图显示令人满意的性能预测KIRC的生存。MRGs-based签名也与免疫细胞浸润和mRNA表达的重要免疫检查点(IDO2, PDCD1 LAG3, FOXP3, TIGIT)。肿瘤突变负担(三甲)景观之间的高收入和低风险组高危人群的三甲水平高于低风险组,更高水平的三甲KIRC预测预后差。此外,KIRC高危组患者更有可能体验到的免疫逃逸。 At last, we found patients with KIRC in the high-risk group were more sensitive to several chemotherapy drugs such as sunitinib, gefitinib, nilotinib, and rapamycin than patients with KIRC in the low-risk group. Our study successfully constructed and validated an MRGs-based signature that can predict clinical characteristics, prognosis, level of immune infiltration, and responsiveness to immunotherapy and chemotherapy drugs in patients with KIRC. SN - 1687-8450 UR - https://doi.org/10.1155/2022/3487859 DO - 10.1155/2022/3487859 JF - Journal of Oncology PB - Hindawi KW - ER -